The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Sex Hormones and Risk of Liver Tumor
Abstract
The liver is morphologically and functionally modulated by sex hormones. Long‐term use of oral contraceptives (OCs) and anabolic androgenic steroids (AASs) can induce both benign (hemangioma, adenoma, and focal nodular hyperplasia [FNH]) and malignant (hepatocellular carcinoma [HCC]) hepatocellular tumors. Hepatic adenomas (HAs) are rare, benign neoplasms usually occurring in young women, the development and the complications of which have been related to the strength of OCs and the duration of their use. HA incidence has fallen since the introduction of pills containing smaller amounts of estrogens. FNH is a benign lesion, most commonly seen in young women, which is thought to represent a local hyperplastic response of hepatocytes to a vascular abnormality. Because of the female predominance and the young age at onset, a role of female hormones has been suggested. Furthermore, a large proportion of women with FNH (50–75%) are OC users. Liver hemangiomas (LHs) are the most common benign liver tumors and are seen more commonly in young adult females. The female predilection and clinical observations of LH growth under conditions of estrogenic exposure suggest a possible role for estrogen in the pathogenesis of LHs. HCC has become one of the most widespread tumors in the world in recent years, representing the sixth leading cancer and the third most common cause of death from cancer. Apart from liver cirrhosis, numerous other factors responsible for its onset have been proposed: hepatitis infections from virus B (HBV) and C (HCV), alcohol, smoking, and aflatoxin. However, regardless of etiology, chronic liver diseases progress at unequal rates in the two sexes, with the major sequelae, such as cirrhosis and HCC, being more frequent in men than in women. These epidemiological data have prompted researchers to investigate the relationship between sex hormones and liver tumors. The human liver expresses estrogen and androgen receptors and experimentally both androgens and estrogens have been implicated in stimulating hepatocyte proliferation and may act as liver tumor inducers or promoters.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Landis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1998) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.48.1.6 · Cited by 2,341
POSSIBLE ASSOCIATION BETWEEN BENIGN HEPATOMAS AND ORAL CONTRACEPTIVES
BAUM, J. (1973) · The Lancet · doi:10.1016/s0140-6736(73)92594-4 · Cited by 611
Epidemiology of hepatocellular adenoma. The role of oral contraceptive use
Rooks, J. B. (1979) · JAMA · doi:10.1001/jama.242.7.644 · Cited by 588
Environmental factors and risk for hepatocellular carcinoma
Yu, M. C., & Yuan, J.-M. (2004) · Gastroenterology · doi:10.1016/j.gastro.2004.09.018 · Cited by 426
Epidemiology of Hepatocellular Carcinoma
El-Serag, H. B. (2001) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70155-0 · Cited by 327
Epidemiology, Risk Factors, and Natural History of Hepatocellular Carcinoma
MONTALTO, G., CERVELLO, M., GIANNITRAPANI, L., DANTONA, F., TERRANOVA, A., & CASTAGNETTA, L. A. M. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04090.x · Cited by 312
Self-citationTamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial
(1998) · The Lancet · doi:10.1016/s0140-6736(98)01259-8 · Cited by 202
Oral contraceptives and hepatocellular carcinoma.
Neuberger, J., Forman, D., Doll, R., & Williams, R. (1986) · BMJ · doi:10.1136/bmj.292.6532.1355 · Cited by 168
Characteristics of hepatocellular carcinoma in Italy
Stroffolini, T., Andreoné, P., Andriulli, A., Ascione, A., Craxì, A., Chiaramonte, M., Galante, D., Manghisi, O. G., Mazzanti, R., Medaglia, C., et al. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80122-0 · Cited by 153
Yu, M. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.24.2023 · Cited by 148
Tanaka, K., Sakai, H., Hashizume, M., & Hirohata, T. (2000) · PubMed · Cited by 140
Grimaldi, C. H., Bleiberg, H., Gay, F., Messner, M., Rougier, P. R., Kok, T. C., Cirera, L., Cervantes, A. M. R., Grève, J. D., Paillot, B., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.411 · Cited by 132
The effect of estrogen and tamoxifen on hepatocyte proliferation in Vivo and in Vitro
Francavilla, A., Polimeno, L., Leo, A. D., Barone, M., Ove, P., Coetzee, M. L., Eagon, P. K., Makowka, L., Ambrosino, G., Mazzaferro, V., et al. (1989) · Hepatology · doi:10.1002/hep.1840090417 · Cited by 128
Ohnishi, S., Murakami, T., Moriyama, T., et al. (1986) · Hepatology · doi:10.1002/hep.1840060320 · Cited by 112
Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma.
Villa, E., Camellini, L., Dugani, A., Zucchi, F., Grottola, A., Merighi, A., Buttafoco, P., Losi, L., & Manenti, F. (1995) · PubMed · Cited by 109
Liu, C.-L., Fan, S.-T., Ng, I. O., et al. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01688.x · Cited by 93
Nakao, A., Sakagami, K., Nakata, Y., et al. (2000) · Journal of Gastroenterology · doi:10.1007/s005350070081 · Cited by 90
Local estrogen formation by nontumoral, cirrhotic, and malignant human liver tissues and cells.
CASTAGNETTA, L. A. M., Agostara, B., Montalto, G., Polito, L. M., Campisi, I., Saetta, A., Itoh, T., Yu, B., Chen, S., & Carruba, G. (2003) · PubMed · Cited by 47
Self-citationOESTROGEN AND ENDOTHELIAL CELL ANGIOGENIC ACTIVITY
Schnaper, H. W., McGowan, K. A., Kim‐Schulze, S., & Cid, M. C. (1996) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1996.tb02605.x · Cited by 46
Carcinogenic Effects of Diethylstilbestrol in Male Syrian Golden Hamsters and European Hamsters 2
Reznik-Schüller, H. M. (1979) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/62.4.1083 · Cited by 40
Characterization of estrogen receptor from human liver
Rossini, G. P., Baldini, G., Villa, E., & Manenti, F. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)91629-6 · Cited by 39
Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism
Jiang, S.-Y., Shyu, R., Yeh, M., & Jordan, V. C. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80038-7 · Cited by 37
Cited by
EASL Clinical Practice Guidelines on the management of benign liver tumours
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.001 · Cited by 534
Kishnani, P. S., Austin, S. L., Abdenur, J. E., Arn, P., Bali, D. S., Boney, A., Chung, W. K., Dagli, A. I., Dale, D., Koeberl, D., et al. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.128 · Cited by 499
Glycogen Storage Disease Type III diagnosis and management guidelines
Kishnani, P. S., Austin, S. L., Arn, P., Bali, D. S., Boney, A., Case, L. E., Chung, W. K., Desai, D. M., El-Gharbawy, A., Haller, R., et al. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181e655b6 · Cited by 311
Risks and benefits of dietary isoflavones for cancer
Andres, S., Abraham, K., Appel, K. E., & Lampen, A. (2011) · Critical Reviews in Toxicology · doi:10.3109/10408444.2010.541900 · Cited by 168
Drug-induced liver injury: Is it somehow foreseeable?
Tarantino, G., Minno, M. N. D. D., & Capone, D. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2817 · Cited by 137
Metadata
- Authors
- GIANNITRAPANI, L., SORESI, M., LA SPADA, E., CERVELLO, M., D'ALESSANDRO, N., & MONTALTO, G.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2006-11
- Volume
- 1089
- Issue
- 1
- Pages
- 228-236
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W1994705023
- Cited by
- 298
- References
- 23
- FWCI
- 9.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.